Noscendo GmbH, a Duisburg, Germany-based diagnostics company dedicated to the identification and assessment of bloodstream-associated pathogens and other infections, closed a Series A financing round of unidsclosed amount.
Backers included new investors Earlybird, Paua Ventures and the JIH Family Office and existing investors Wieland Capital and High-Tech Gründerfonds.
The company intends to use the funds for further business expansion and product launch.
Led by Dr. Philip Stevens (CEO), Dr. Peter Haug (CFO & Head of BD&L), Dr. Silke Grumaz, CSO, and Dr. Marcus Benz, COO, Noscendo develops bioinformatic solutions to identify and assess pathogens in bloodstream-associated and related infections. The proprietary diagnostic platform, , which enables the reliable detection of more than 1,500 bacteria, DNA viruses, fungi and parasites in the patient’s bloodstream based on cell-free DNA (cfDNA), has been validated together with German clinicians. To this end, the company collaborates with leading hospitals, development partners, logistics providers, innovation-driven health service providers and health insurance funds.